The Gaucher Initiative is Genzyme's partnership with Project HOPE that brings Cerezyme therapy to Gaucher disease patients who live in developing countries where reimbursement is not yet a reality. Since the program began in 1999, more than 200 patients who otherwise would not have had access to Cerezyme have received it free of charge.

Genzyme runs the European Cerezyme Access Program (ECAP) which provides free treatment to Gaucher patients in Eastern Europe.

Patients who live in countries where reimbursement is available can still face circumstances in which they cannot access treatment. The International Charitable Access Program (ICAP) provides Genzyme's four enzyme replacement therapies at no cost to patients who live outside of the United States.

Similar to the ICAP program, the Charitable Access Program (CAP) provides Genzyme's four enzyme replacement therapies free of charge to U.S. patients who are not covered by any insurance program and lack the financial resources to obtain treatment.

In partnership with the American Kidney Fund, Genzyme created the Renal Patient Assistance Program (RPAP), which provides Renagel and Hectorol to patients who have no other means of access. Since the program was launched in 2001, nearly 16,000 patients have received free treatment through RPAP.